Actively Recruiting

Age: 18Years +
All Genders
NCT05461664

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Led by Xinhua Zhang, MD · Updated on 2025-02-26

74

Participants Needed

1

Research Sites

181 weeks

Total Duration

On this page

Sponsors

X

Xinhua Zhang, MD

Lead Sponsor

P

Peking University Cancer Hospital & Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.

CONDITIONS

Official Title

Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients who are aged 18 years.
  • Gastrointestinal stromal tumors confirmed by histopathological examination, and CD- and/or DOG-1-positive by immunohistochemistry.
  • Presence of mRECIST v1.1-compliant lesions with at least one measurable lesion (non-lymphadenopathy 1.0 cm or 2-fold scan slice thickness).
  • Treatment with Avapritinib.
  • Patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at screening.
  • Patient informed consent and signed written consent form.
  • The patient was compliant and voluntarily scheduled for follow-up, treatment, laboratory tests, and other study procedures.
Not Eligible

You will not qualify if you...

  • KIT or PDGFRA wild type.
  • Failure to complete continuous atorvastatin for at least 15 days due to intolerability or disease progression.
  • Other serious acute or chronic physical or mental problems, or laboratory abnormalities, may increase the risk associated with participation in the study or use of drugs, or interfere with the judgment of the study results and, in the judgment of the investigator, are not considered appropriate for participation in the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, China, 510080

Actively Recruiting

Loading map...

Research Team

X

Xinhua Zhang, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here